<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5206">
  <stage>Registered</stage>
  <submitdate>21/04/2015</submitdate>
  <approvaldate>21/04/2015</approvaldate>
  <nctid>NCT02431312</nctid>
  <trial_identification>
    <studytitle>Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects</studytitle>
    <scientifictitle>Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability &amp; Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HBV-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Group A: INO-1800 alone delivered by EP
Other interventions - Group B: INO-1800 + INO-9112 delivered by EP
Treatment: drugs - Nucleos(t)ide Analogue Treatment

Experimental: Group A, low dose, standard regimen - 0.3mg INO-1800 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment

Experimental: Group A, mid dose, standard regimen - 2mg INO-1800 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment

Experimental: Group A, high dose, standard regimen - 9mg INO-1800 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment

Experimental: Group B, mid dose, standard regimen - 2mg INO-1800 + 0.25mg INO-9112 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment

Experimental: Group B, high dose, standard regimen - 9mg INO-1800 + 0.25mg INO-9112 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment

Active Comparator: Active Control - Continue treatment with nucleos(t)ide analogue treatment


Other interventions: Group A: INO-1800 alone delivered by EP


Other interventions: Group B: INO-1800 + INO-9112 delivered by EP


Treatment: drugs: Nucleos(t)ide Analogue Treatment
Continue treatment with Nucleos(t)ide Analogue Treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety Assessment (Composite of multiple measures: pain (VAS), adverse events, lab abnormalities, changes in vital signs) - Composite outcome measure consisting of multiple measures, including:
Local pain immediately after Study Treatment/EP and at select times using a visual analog scale (VAS) from 0 to 10, with 0 representing "No Pain" and 10 representing "Worst Pain"
Frequency and severity of local and systemic events for at least 7 days after Study Treatment/EP
Frequency and severity of laboratory abnormalities
Frequency and severity of all adverse events
Changes in vital signs</outcome>
      <timepoint>Signing of ICF through up to 76 weeks following the first dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity Assessment - Composite outcome measure consisting of multiple measures, including
Breadth and Magnitude of antigen specific cellular immune responses
Interferon-? ELISpot
Flow Cytometry for T-cell activation, cytolytic phenotype, memory phenotype
Breadth and Magnitude of antigen specific ELISA</outcome>
      <timepoint>Baseline (screening and first dose) and select points up to 76 weeks after the first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Viral/Antiviral Assessment - Composite outcome measure consisting of multiple measures, including:
Evaluate effect on HBsAg kinetics as measured in the quantitative HBsAg assay
Evaluate effect on maintenance of HBV DNA suppression (&lt; 90 IU/ml) as measured in the quantitative viral load assay</outcome>
      <timepoint>Screening and/or first dose and select points up to 76 weeks after the first dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>INCLUSION CRITERIA:

          -  Chronic Hepatitis B virus infection

          -  Negative for Hepatitis A IgM, C, D and HIV

          -  Liver biopsy, Fibroscan® or equivalent elastography-based test obtained within the
             past 6 mon demonstrating liver disease without evidence of bridging fibrosis or
             cirrhosis supported by platelet count greater than the central laboratory LLN at
             screening

          -  Positive for Hepatitis B surface antigen (=250 IU/mL at screening)

          -  Nucleos(t)ide treatment for at least 1 year with ongoing nucleos(t)ide analogue
             treatment at randomization

          -  HBV DNA &lt;90 IU/mL for =6 mon prior to randomization

          -  Screening laboratory values within normal range

          -  ALT =1.5x ULN from 2 measurements separated by at least 14 days during the 6 mon prior
             to randomization and ALT at screening =1.5x ULN

          -  AST, TBili, DBili, GGT, Alk Phos and albumin within normal range or judged to be not
             clinically significant by PI and medical monitor at screening

          -  For men and women who are not postmenopausal [i.e. = 12 months of non-therapy-induced
             amenorrhea, confirmed by follicle stimulating hormone (FSH), if not on hormone
             replacement] or surgically sterile (vasectomy in males or absence of ovaries and/or
             uterus in females) agreement to remain abstinent or use 1 highly effective or combined
             contraceptive methods that result in a failure rate of &lt; 1% per year during the
             treatment period and at least through week 12 after last dose

        EXCLUSION CRITERIA:

          -  Pregnant or breastfeeding females

          -  Positive serum pregnancy test at screening or positive urine pregnancy test at
             randomization

          -  Use of topical corticosteroids at or near the intended administration site

          -  Autoimmune disorders, transplant recipients, other immunosuppression including any
             concurrent condition requiring the use of immunosuppressive/immunomodulating agents
             (eye drop-containing and infrequent inhaled corticosteroids are permissible)

          -  Need for systemic antiviral treatment (other than for chronic hepatitis B infection)

          -  Documented history or other evidence of decompensated liver disease (e.g., ascites,
             bleeding from esophageal varices, Child-Pugh clinical classification B or C)

          -  History of liver cirrhosis demonstrated by biopsy, Fibroscan® or equivalent
             elastography-based test

          -  History of other evidence of a medical condition associated with chronic liver disease
             [e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, non-alcoholic
             steatohepatitis (NASH), toxin exposure, thalassemia, etc.]

          -  Documented history or other evidence of metabolic liver disease within 1yr of
             randomization

          -  Abnormal renal function including serum creatinine &gt;ULN or calculated creatinine
             clearance &lt;70 mL/min (using the Cockcroft Gault formula)

          -  History of or suspicion of HCC

          -  Screening alpha fetoprotein =13 ng/mL

          -  Prior history or current malignancy other than adequately treated BCC, unless history
             of BCC is near intended administration site

          -  History of significant medical conditions [e.g., cardiac (including ventricular or
             supraventricular arrhythmias), renal disease, pulmonary, gastrointestinal,
             neurological]

          -  Significant acute infection (e.g., influenza, local infection) or any other clinically
             significant illness within 2 weeks of randomization

          -  Administration of any blood product within 3 mon of randomization

          -  History of seizures (unless seizure free for 5yrs)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>Nepean Hospital - Kingswood</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>2747 - Kingswood</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Pasig City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan County</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Inovio Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open-label study to evaluate the safety, tolerability, and immunogenicity of dose
      combinations of INO-1800 (DNA plasmids encoding HBsAg and HBcAg) and INO-9112 (DNA plasmid
      encoding human interleukin 12) delivered by electroporation (EP) in 90 (ninety) nucleos(t)ide
      analogue treated patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02431312</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Scott White, MD</name>
      <address>Inovio Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>